UNSPSC 51262503: Guanoxan

This classification denotes a guanidine and antihypertensive agent with the molecular formula C10H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V0MRL0R5Y, chemically known as guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)- (9ci) but generally known as guanoxan, which bears US NIH Compound Identifier 16564. European Medicines Agency schedules Guanoxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07989MIG.

UNSPSC 51262503 Guanoxan, a Commodity code, does not align with the actual work state and local governments are soliciting under this classification. The recent opportunity posted by Seminole County, Florida (IFB 60459723LAS) sought procurement of naloxone and safe drug deactivation systems — emergency medical and harm-reduction supplies — which fall outside the scope of guanoxan, a cardiovascular pharmaceutical. The mismatch suggests either a misclassification in the county's procurement system or that this UNSPSC code sees limited or no relevant recent activity among state and local buyers.

The single identified opportunity from Seminole County required 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under an IFB posted June 30, 2026, with a response deadline of July 26, 2023. The contract included a two-year initial term with an optional one-year renewal, standard compliance requirements (drug-free workplace certification, E-Verify), and insurance coverage mandates. The source provides no additional state or local opportunities under this commodity code and no evidence of repeat buyers or geographic concentration. The absence of relevant recent solicitations and the apparent code-scope mismatch suggest this code warrants close monitoring rather than active pursuit at this time.